Gene screening and prevention of hereditary breast cancer: a clinical view

被引:3
|
作者
Klijn, JGM [1 ]
Meijers-Heijboer, H
机构
[1] Dr Daniel Den Hoed Canc Ctr, Rotterdam Family Canc Clin, Dept Med Oncol, Rotterdam, Netherlands
[2] Erasmus Univ, Ctr Med, Rotterdam, Netherlands
来源
EJC SUPPLEMENTS | 2003年 / 1卷 / 01期
关键词
D O I
10.1016/S1359-6349(03)00005-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nowadays, the major tasks of the increasing number of family cancer clinics are to provide general information about cancer, to perform risk assessment, to offer (presymptomatic) DNA-testing, to advise on lifestyle, to take steps for early detection and prevention of cancer, for psychological support and to carry out research programmes by a multidisciplinary approach. In approximately 25-30%,, of the families with a hereditary pattern of breast cancer a germline mutation can be demonstrated, most commonly in the BRCA1 and BRCA2 genes. Mutations in these genes are associated with high life-time risks of breast and ovarian cancer. The introduction of MR1 increased the sensitivity for early detection of breast cancer in comparison with mammography. Thus far, prophylactic bilateral total mastectomy is the most effective and safest way of prevention but prophylactic oophorectomy and chemopreventionare reasonable alternatives. In particular young women with children make use of DNA-testing and surgical prevention. By a shared decision-making process, the patient and her medical doctor have to make the right choice of management policy based on her individual circumstances. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 50 条
  • [1] Prevention and Screening in Hereditary Breast and Ovarian Cancer
    Zeichner, Simon B.
    Stanislaw, Christine
    Meisel, Jane L.
    [J]. ONCOLOGY-NEW YORK, 2016, 30 (10): : 896 - 904
  • [2] The Prevention of Hereditary Breast and Ovarian Cancer: A Personal View
    Steven Narod
    [J]. Hereditary Cancer in Clinical Practice, 2 (1)
  • [3] Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
    Paluch-Shimon, S.
    Cardoso, F.
    Sessa, C.
    Balmana, J.
    Cardoso, M. J.
    Gilbert, F.
    Senkus, E.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : v103 - v110
  • [4] The prevention of hereditary breast cancer
    Rodriquez, Estelarnari
    Domchek, Susan M.
    [J]. SEMINARS IN ONCOLOGY, 2007, 34 (05) : 401 - 405
  • [5] Screening for hereditary breast cancer
    Dent, Rebecca
    Warner, Ellen
    [J]. SEMINARS IN ONCOLOGY, 2007, 34 (05) : 392 - 400
  • [6] Prevention and management of hereditary breast cancer
    Narod, SA
    Offit, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) : 1656 - 1663
  • [7] Hormonal prevention of hereditary breast cancer
    Narod, SA
    [J]. CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS, 2001, 952 : 36 - 43
  • [8] A Clinical Risk Model for Personalized Screening and Prevention of Breast Cancer
    Eriksson, Mikael
    Czene, Kamila
    Vachon, Celine
    Conant, Emily F.
    Hall, Per
    [J]. CANCERS, 2023, 15 (12)
  • [9] Breast Cancer Screening and Prevention
    Nattinger, Ann B.
    Mitchell, Julie L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 164 (11) : ITC81 - ITC94
  • [10] The role of surgery in hereditary breast cancer prevention
    José Díaz-Faes
    [J]. Revista de Oncología, 2003, 5 (6): : 313 - 314